BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12443673)

  • 1. Emergency response vaccines--a challenge for the public sector and the vaccine industry.
    Milstien J; Lambert S
    Vaccine; 2002 Nov; 21(1-2):146-54. PubMed ID: 12443673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.
    AIDS; 2001 May; 15(7):W27-44. PubMed ID: 11399975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines, inspiring innovation in health.
    Pagliusi S; Dennehy M; Kim H;
    Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for the world: major challenges for the future.
    Lambert PH
    Southeast Asian J Trop Med Public Health; 1997; 28 Suppl 2():122-6. PubMed ID: 9561647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency response vaccines: lessons learned in response to communicable diseases.
    Milstien J
    Expert Opin Biol Ther; 2003 Oct; 3(7):1121-31. PubMed ID: 14519076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps in vaccine financing for underinsured children in the United States.
    Lee GM; Santoli JM; Hannan C; Messonnier ML; Sabin JE; Rusinak D; Gay C; Lett SM; Lieu TA
    JAMA; 2007 Aug; 298(6):638-43. PubMed ID: 17684186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of South Africa's public-private partnership for the localisation of vaccine research, manufacture and distribution.
    Walwyn DR; Nkolele AT
    Health Res Policy Syst; 2018 Mar; 16(1):30. PubMed ID: 29587777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
    Mahoney R
    J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States vaccine research: a delicate fabric of public and private collaboration. National Vaccine Advisory Committee.
    Pediatrics; 1997 Dec; 100(6):1015-20. PubMed ID: 9411380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the vaccines industry in Mission Grand Convergence.
    Almond J; Medaglini D
    Vaccine; 2017 Jan; 35 Suppl 1():A24-A28. PubMed ID: 28017440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
    Hendriks J
    Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and changes: immunization program managers share perspectives in a 2012 national survey about the US immunization system since the H1N1 pandemic response.
    Seib K; Chamberlain A; Wells K; Curran E; Whitney EA; Orenstein WA; Hinman AR; Omer SB
    Hum Vaccin Immunother; 2014; 10(10):2915-21. PubMed ID: 25483633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines: Shaping global health.
    Pagliusi S; Ting CC; Lobos F;
    Vaccine; 2017 Mar; 35(12):1579-1585. PubMed ID: 28237501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine development and deployment: opportunities and challenges in India.
    Gupta SS; Nair GB; Arora NK; Ganguly NK
    Vaccine; 2013 Apr; 31 Suppl 2():B43-53. PubMed ID: 23598492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Global Vaccine Injury Compensation System.
    Halabi SF; Omer SB
    JAMA; 2017 Feb; 317(5):471-472. PubMed ID: 28114657
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of the private sector in vaccination service delivery in India: evidence from private-sector vaccine sales data, 2009-12.
    Sharma A; Kaplan WA; Chokshi M; Zodpey SP
    Health Policy Plan; 2016 Sep; 31(7):884-96. PubMed ID: 26976803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.